These patients were allocated into 2 groups, i.e., IL-34-positive group (IL-34+ group, IL-34 detectable SLE patients) and the IL-34-negative group (IL-34− group, IL-34 undetectable SLE patients), based on their IL-34 status. The gene discussed is IL34; the disease is systemic lupus erythematosus.